Calcium Citrate + Calcitriol interactions
Checked as Calcium citrate + Calcitriol in this data source.
Full monograph for Calcium Citrate + CalcitriolCheck it against another medicine
Medicines
468 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Alendronic Acid + Vitamin D3via Calcium citrate, Calcitriol | Major | Absorption · Synergy · Unknown | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive…3 documented mechanisms | 14 sources — open the full entry |
| Algae Calcium + Vitamin D3via Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxidevia Calcium citrate, Calcitriol | Major | Absorption · Others · Synergy | The concomitant administration of aluminum-containing products (e.g., antacids and phosphate binders) and citrates may significantly increase serum aluminum…3 documented mechanisms | 16 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethiconevia Calcium citrate, Calcitriol | Major | Absorption · Others · Synergy | The concomitant administration of aluminum-containing products (e.g., antacids and phosphate binders) and citrates may significantly increase serum aluminum…3 documented mechanisms | 16 sources — open the full entry |
| Calcium + Vitamin D3 + Multimineralvia Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C + Vitamin D3via Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3via Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 + Multimineralsvia Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Phosphate [Milk source] + Vitamin D3via Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Cholecalciferol [Vitamin D3]via Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Conventional Calcium + Vitamin D3via Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Coral Calcium + Vitamin D3via Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Doxercalciferolvia Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Eggshell Calcium + Vitamin D3via Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Eggshell Calcium + Vitamin D3 + 19 Vitamin & Mineralsvia Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Erdafitinibvia Calcitriol, Calcium citrate | Major | Others | Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be…2 documented mechanisms | 1 sources — open the full entry |
| Ibandronic Acid + Algae Calcium + Vitamin D3via Calcium citrate, Calcitriol | Major | Absorption · Synergy · Unknown | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive…3 documented mechanisms | 14 sources — open the full entry |
| Ibandronic Acid + Coral Calcium + Vitamin D3via Calcium citrate, Calcitriol | Major | Absorption · Synergy · Unknown | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive…3 documented mechanisms | 14 sources — open the full entry |
| Paricalcitolvia Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Vitamin C + Vitamin D3 + Folic acidvia Calcitriol | Major | Synergy · Unknown | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive…2 documented mechanisms | 5 sources — open the full entry |
| Alendronic acidvia Calcium citrate, Calcitriol | Moderate | Absorption · Unknown | INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to…2 documented mechanisms | 9 sources — open the full entry |
| Aluminium Oxide + Magnesium Trisilicatevia Calcitriol | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Amlodipine Besilatevia Calcium citrate, Calcitriol | Moderate | Antagonism · Unknown | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…2 documented mechanisms | 46 sources — open the full entry |
| Amlodipine Besilate + Atenololvia Calcium citrate, Calcitriol | Moderate | Absorption · Antagonism · Unknown | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…4 documented mechanisms | 53 sources — open the full entry |
| Amlodipine Besilate + Atorvastatinvia Calcium citrate, Calcitriol | Moderate | Antagonism · Unknown | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…3 documented mechanisms | 46 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloridevia Calcium citrate, Calcitriol | Moderate | Antagonism · Unknown | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…2 documented mechanisms | 46 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomilvia Calcium citrate, Calcitriol | Moderate | Antagonism · Unknown | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…2 documented mechanisms | 46 sources — open the full entry |
| Amlodipine Besilate + Telmisartanvia Calcium citrate, Calcitriol | Moderate | Antagonism · Unknown | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…3 documented mechanisms | 46 sources — open the full entry |
| Amlodipine Besilate + Valsartanvia Calcium citrate, Calcitriol | Moderate | Antagonism · Unknown | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…3 documented mechanisms | 46 sources — open the full entry |
| Atenololvia Calcium citrate, Calcitriol | Moderate | Absorption · Unknown | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…2 documented mechanisms | 7 sources — open the full entry |
| Atenolol + Chlorthalidonevia Calcium citrate, Calcitriol | Moderate | Absorption · Synergy · Unknown | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…4 documented mechanisms | 22 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidonevia Calcium citrate, Calcitriol | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…2 documented mechanisms | 15 sources — open the full entry |
| Baloxavir Marboxilvia Calcium citrate | Moderate | Absorption | Coadministration with polyvalent cation-containing products may decrease the plasma concentrations and therapeutic efficacy of baloxavir. The proposed… | 3 sources — open the full entry |
| Betaxolol Hydrochloridevia Calcium citrate | Moderate | Absorption | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism… | 7 sources — open the full entry |
| Bimatoprost + Timololvia Calcium citrate, Calcitriol | Moderate | Absorption · Unknown | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…3 documented mechanisms | 7 sources — open the full entry |
| Bisoprolol Fumaratevia Calcium citrate, Calcitriol | Moderate | Absorption · Unknown | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…2 documented mechanisms | 7 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilatevia Calcium citrate, Calcitriol | Moderate | Absorption · Antagonism · Unknown | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…4 documented mechanisms | 53 sources — open the full entry |
| Bisoprolol Fumarate + Hydrochlorothiazidevia Calcium citrate, Calcitriol | Moderate | Absorption · Synergy · Unknown | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…4 documented mechanisms | 22 sources — open the full entry |
| Brimonidine Tartrate + Timolol Maleatevia Calcium citrate, Calcitriol | Moderate | Absorption · Unknown | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…3 documented mechanisms | 7 sources — open the full entry |
| Brinzolamide + Timololvia Calcium citrate, Calcitriol | Moderate | Absorption · Unknown | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…2 documented mechanisms | 7 sources — open the full entry |
| Calcium acetate + Magnesium carbonatevia Calcitriol | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Candesartan Cilexetil + Hydrochlorothiazidevia Calcium citrate, Calcitriol | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…2 documented mechanisms | 15 sources — open the full entry |
| Carbamazepinevia Calcitriol | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Carvedilolvia Calcium citrate, Calcitriol | Moderate | Absorption · Unknown | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…2 documented mechanisms | 7 sources — open the full entry |
| Chlorthalidonevia Calcium citrate, Calcitriol | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…2 documented mechanisms | 15 sources — open the full entry |
| CiprofloxacinbaseOphthalmicvia Calcium citrate, Calcitriol | Moderate | Absorption · Unknown | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…2 documented mechanisms | 32 sources — open the full entry |
| Ciprofloxacin + Dexamethasonevia Calcium citrate, Calcitriol | Moderate | Absorption · Unknown | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…3 documented mechanisms | 32 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetatevia Calcium citrate, Calcitriol | Moderate | Absorption · Unknown | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…2 documented mechanisms | 32 sources — open the full entry |
| Clobetasol Propionate + Ofloxacin + Ornidazole + Terbinafinevia Calcium citrate, Calcitriol | Moderate | Absorption · Unknown | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…3 documented mechanisms | 32 sources — open the full entry |
| Deferipronevia Calcium citrate | Moderate | Absorption | INTERVAL: Deferiprone has the potential to bind polyvalent cations such as aluminum, iron and zinc, which may reduce its effectiveness. However, concurrent use… | 1 sources — open the full entry |
Food & lifestyle
bran
ModerateAbsorption
Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
What to do: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
6 sources
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):
- Cerner Multum, Inc. "Australian Product Information." O 0
- Agencia Espa?ola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaci��n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
- Mangels AR "Bone nutrients for vegetarians." Am J Clin Nutr 100 (2014): epub
- Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8
grain
ModerateAbsorption
Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
What to do: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
6 sources
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):
- Cerner Multum, Inc. "Australian Product Information." O 0
- Agencia Espa?ola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaci��n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
- Mangels AR "Bone nutrients for vegetarians." Am J Clin Nutr 100 (2014): epub
- Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8
rhubarb
ModerateAbsorption
Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
What to do: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
6 sources
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):
- Cerner Multum, Inc. "Australian Product Information." O 0
- Agencia Espa?ola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaci��n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
- Mangels AR "Bone nutrients for vegetarians." Am J Clin Nutr 100 (2014): epub
- Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8
spinach
ModerateAbsorption
Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
What to do: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
6 sources
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):
- Cerner Multum, Inc. "Australian Product Information." O 0
- Agencia Espa?ola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaci��n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
- Mangels AR "Bone nutrients for vegetarians." Am J Clin Nutr 100 (2014): epub
- Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8
Conditions
Conditions in which Calcium Citrate + Calcitriol needs care, as documented in this source.
Arrhythmias, Cardiac
MajorVitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.
3 sources
- "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Calderol (calcifediol)." Organon (2001):
Cardiac Conduction System Disease
MajorCalcium is involved in cardiac muscle contraction and electrical impulse conduction. Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease. Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias. Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.
2 sources
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation (2001):
Hypercalcemia
MajorVitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.
4 sources
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical (2001):
- "Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc (2002):
- "Product Information. Drisdol (ergocalciferol)." sanofi-aventis (2016):
Hyperphosphatemia
MajorElevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body. Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment). Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. These complexes are eliminated in the feces. Clinical monitoring of serum calcium and phosphate concentrations is necessary.
2 sources
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation (2001):
Kidney Diseases
MajorErgocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.
3 sources
- "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Calderol (calcifediol)." Organon (2001):
Kidney Diseases
MajorAbsorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment. Hyperphosphatemia occurs during renal failure. Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure. Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.
2 sources
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation (2001):
Malabsorption Syndromes
MajorCalcium is absorbed from the intestinal tract by active transport and passive diffusion. Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium. Calcium is available in oral and parenteral formulations.
2 sources
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation (2001):
Sarcoidosis
MajorHypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis. Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma. Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.
3 sources
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation (2001):
- Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division (1998):
Water-Electrolyte Imbalance
MajorVitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.
4 sources
- "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Calderol (calcifediol)." Organon (2001):
- "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical (2001):
Diseases requiring dialysis
ModerateCalcitriol increases inorganic phosphate levels in serum and caution should be used in patients with renal impairment to maintain adequate phosphorus levels and avoid ectopic calcification. A non-aluminum phosphate-binding compound and a low phosphate diet should be used to control serum phosphorus levels in patients undergoing dialysis.
1 source
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
Liver Diseases
ModerateVitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.
3 sources
- "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Calderol (calcifediol)." Organon (2001):
Therapeutic duplication
Drug classes that overlap with Calcium Citrate + Calcitriol, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
vitamin d analogs
The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'vitamin d analogs' category.
Example product in the source data (US market): Os-cal extra d3
vitamin d analogs
The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'vitamin d analogs' category.
Example product in the source data (US market): Ortho df
vitamin d analogs
The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'vitamin d analogs' category.
Example product in the source data (US market): Alendronate/cholecalciferol